表皮生长因子受体酪氨酸激酶抑制剂耐药的非小细胞肺癌:T790M突变阳性癌的CT特征
回顾性分析304例一线EGFR-TKI治疗后重新活检的非小细胞肺癌患者,47.4%为T790M突变阳性;TKI失败后CT上周围型肿瘤、胸膜牵拉征和空气支气管征与T790M突变阳性相关,T790M阳性患者从TKI开始至重新活检的持续时间更长。
要点
- TKI失败后CT显示周围型肿瘤、胸膜牵拉征和空气支气管征与T790M突变阳性相关。
- T790M阳性患者从TKI开始至重新活检的持续时间长于阴性患者(20.5 vs 13.6个月)。
- T790M阳性患者自重新活检起的累积生存显著更长,但中位生存时间无统计学差异。
核心结论
- 一线EGFR-TKI治疗失败的非小细胞肺癌患者中,重新活检时CT显示周围型肿瘤伴血管集束、胸膜牵拉征和空气支气管征与T790M突变显著相关。
研究设计与样本
- 回顾性研究纳入304例一线EGFR-TKI治疗后重新活检的非小细胞肺癌患者;重新活检方法包括CT或透视引导下肺活检(n=105)、支气管内超声或支气管镜引导下活检(n=66)、胸水分析(n=47)、其他实体器官活检(n=43)、超声引导下腋窝或锁骨上淋巴结活检(n=31)及脑脊液分析(n=12);分析初诊和重新活检时的CT表现。
关键影像表现/征象
- TKI失败后CT上周围型肿瘤与T790M突变阳性相关(OR 2.6,P = .01)。
- TKI失败后CT上胸膜牵拉征与T790M突变阳性相关(OR 5.0,P < .001)。
- TKI失败后CT上空气支气管征与T790M突变阳性相关(OR 4.0,P = .006)。
诊断标准与关键数值
- 重新活检时T790M突变阳性率为47.4%(144/304)。
- 肺活检患者中T790M突变阳性比例为50%(53/106),原发肺病灶活检患者中为47%(36/77)。
- T790M阳性患者从TKI开始至重新活检的持续时间为20.5个月,阴性患者为13.6个月(P < .001)。
临床应用与阅片要点
- 重新活检时CT显示周围型肿瘤、胸膜牵拉征和空气支气管征,可能提示T790M突变阳性,可结合临床考虑重新活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the clinical and CT characteristics of T790M mutation-positive non-small cell lung cancer (NSCLC) after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy failure. Materials and Methods A retrospective study of 304 patients with NSCLC who underwent rebiopsy after first-line EGFR-TKI therapy was conducted. Rebiopsy methods included CT- or fluoroscopy-guided lung biopsies (n = 105), endobronchial US- or bronchofibroscopy-guided biopsies (n = 66), pleural fluid analysis (n = 47), other solid organ biopsies (n = 43), US-guided axillary or supraclavicular lymph node biopsies (n = 31), and cerebrospinal fluid analysis (n = 12). CT findings at the initial diagnosis and rebiopsy were analyzed. Progression-free survival, the duration from the start of TKI therapy to rebiopsy, and survival were calculated. Results At rebiopsy, 144 (47.4%) patients were T790M mutation positive. The percentages of T790M mutation-positive NSCLCs were similar in 106 patients with rebiopsy of the lungs (53 [50%] of 106) and in 77 patients with rebiopsy of the primary lung lesions (36 [47%] of 77). T790M mutation positivity was associated with peripheral tumors (odds ratio [OR], 2.6; P = .01), pleural tag (OR, 5.0; P < .001), and air bronchogram (OR, 4.0; P = .006) at CT after TKI failure. The duration from the start of TKI therapy to rebiopsy was longer in T790M mutation-positive than in T790M mutation-negative patients (20.5 vs 13.6 months; P < .001). Cumulative survival from the time of rebiopsy to the last follow-up was significantly longer in patients with T790M mutation-positive lung cancers (P = .014). However, median survival time after rebiopsy was not statistically different between patients with and those without T790M mutation. Conclusion Peripheral tumor location with vascular convergence, the presence of a pleural tag, and air bronchogram of lung lesions at CT at the time of rebiopsy were significantly associated with T790M mutation in patients with non-small cell lung cancer after first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy failure. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Koo HJ, Kim MY, Park S, et al. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer. Radiology. 2018. PMID: 30015588. doi:10.1148/radiol.2018180070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。